Share Email Print
cover

Proceedings Paper

Photodynamic therapy of dysplasia in Barrett's esophagus: an update
Author(s): Masoud Panjehpour; Bergein F. Overholt
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy using Photofrin has been used as an alternative to esophagectomy for patients with dysplasia or superficial cancer associated with Barrett's esophagus. In this update we present the results in 71 patients treated and followed for 6-72 months. 54 patients had high grade dysplasia/early cancer, and 17 had low grade dysplasia. 22 Patients had early cancer and 1 had T2 cancer. Three separate PDT treatments were required in 3 patients, 2 in 20 patients and 1 in 48. All patients were maintained on omeprazole. Patients received a photofrin dose of 2 mg/kg followed two days later by 630 nm laser light from an either argon/dye laser or KTP/dye laser. The majority of patients received light from a balloon light delivery device. Dysplasia and carcinoma was eliminated or reduced in majority of the cases. 75-80 percent of Barrett's mucosa was replaced by squamous epithelium. 34 patients developed strictures. All responded well to dilation.

Paper Details

Date Published: 8 May 1997
PDF: 10 pages
Proc. SPIE 2972, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy VI, (8 May 1997); doi: 10.1117/12.273506
Show Author Affiliations
Masoud Panjehpour, Thompson Cancer Survival Ctr. (United States)
Bergein F. Overholt, Thompson Cancer Survival Ctr. (United States)


Published in SPIE Proceedings Vol. 2972:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy VI
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top